Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Bausch + Lomb Corporation Common Shares (NY:BLCO)

11.61 +0.10 (+0.87%)
Official Closing Price Updated: 7:00 PM EDT, Jun 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Bausch + Lomb Corporation Common Shares

< Previous 1 2 3 4 Next >
Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:OTLK),(NASDAQ:EYEN),(NYSE:BLCO),(NASDAQ:BMEA) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
Bausch + Lomb Launches Blink® Nourish Lubricating Eye Drops and Blink Boost Lubricating Eye Drops in the United States
From Bausch + Lomb Corporation
Via Business Wire
Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities
From FN Media Group LLC
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO
From Pomerantz LLP
Via GlobeNewswire
Bausch + Lomb to Participate in the 2025 Jefferies Global Healthcare Conference
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Launches New LUMIFY® Preservative Free Redness Reliever Eye Drops in the United States
From Bausch + Lomb Corporation
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO
From Pomerantz LLP
Via GlobeNewswire
Bausch + Lomb Launches Zenlens® CHROMA HOA™ in the United States
From Bausch + Lomb Corporation
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO
From Pomerantz LLP
Via GlobeNewswire
Securities Fraud Investigation Into Bausch + Lomb Corporation (BLCO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
Bausch + Lomb Corporation (BLCO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
Securities Fraud Investigation Into Bausch + Lomb Corporation (BLCO) Announced – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
From Law Offices of Frank R. Cruz
Via Business Wire
Bausch + Lomb Receives European CE Mark Approval for Preloaded LuxLife® Full Range of Vision Intraocular Lens
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces First-Quarter 2025 Results
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Returning enVista® Intraocular Lenses to Market Following Voluntary Recall
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Voluntary Recall of enVista Aspire™, enVista Envy™ and Certain enVista® Monofocal Intraocular Lenses
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Release First-Quarter 2025 Financial Results on April 30
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Launches Arise™ Orthokeratology Lens System in the United States
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results, Provides 2025 Guidance
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Provides Update on Potential Sale
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2024 Financial Results on February 19
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap Biosciences
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Launches enVista Aspire™ Intermediate Optimized Monofocal and Toric Intraocular Lenses in the European Union
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb and Glaucoma Research Foundation Launch Second Annual “Faces of Glaucoma” Campaign and Fundraising Challenge
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Responds to Rumors of a Potential Sale
From Bausch + Lomb Corporation
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.